Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in human glioblastoma

Neuropathology

Volumn 34, Issue 4, 2014, Pages 343-352

  Clara, Carlos Afonso ^a   Marie, Suely K N ^b   de Almeida, José Reynaldo Walther ^a   Wakamatsu, Alda ^b   Oba Shinjo, Sueli Mieko ^b   Uno, Miyuki ^b   Neville, Munro ^c   Rosemberg, Sérgio ^b  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angiogenesis; Glioblastoma; HIF 1 ; PDGF C; VEGF

Indexed keywords

CARMUSTINE; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PLATELET DERIVED GROWTH FACTOR C; VASCULOTROPIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; LYMPHOKINE; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR C; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CAPILLARY DENSITY; CELL NUCLEUS; CELL PROLIFERATION; CORRELATION ANALYSIS; CYTOPLASM; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT RESPONSE; UPREGULATION; BRAIN TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); SURVIVAL; VASCULARIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BRAIN NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84906092909     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12111     Document Type: Article

References (45)

1. Finak G, Bertos N, Pepin F etal. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
2. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
3. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
4. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
5. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8: 579-591.
6. Dvorak HF. VPF/VEGF and the angiogenic response. Semin Perinatol 2000; 24: 75-78.
7. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006; 10: 515-527.
8. Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. FEBS J 2009; 276: 4636-4643.
9. Aase K, Abramsson A, Karlsson L, Betsholtz C, Eriksson U. Expression analysis of PDGF-C in adult and developing mouse tissues. Mech Dev 2002; 110: 187-191.
10. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004; 15: 197-204.
11. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312.
12. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003; 14: 91-98.
13. Cao R, Bråkenhielm E, Li X etal. Angiogenesis stimulated by PDGF-CC: a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002; 16: 1575-1583.
14. Li X, Pontén A, Aase K etal. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000; 2: 302-309.
15. Li X, Kumar A, Zhang F etal. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 2010; 1: 309-314.
16. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008; 5: e19.
17. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62: 3729-3735.
18. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 2007: cm8.
19. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
20. Yoshida D, Kim K, Noha M, Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 2006; 76: 13-21.
21. Bauchet L, Mathieu-Daudé H, Fabbro-Peray P etal. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-Oncol 2010; 12: 725-735.
22. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100: 2235-2241.
23. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610-622.
24. Flynn JR, Wang L, Gillespie DL etal. Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme. Cancer 2008; 113: 1032-1042.
25. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
26. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005; 27: 371-377.
27. Dallas NA, Samuel S, Xia L etal. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937.
28. Yao Y, Kubota T, Takeuchi H, Sato K. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathol 2005; 25: 201-206.
29. Sica G, Lama G, Anile C etal. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int J Oncol 2011; 38: 41-49.
30. Pietras K, Sjöblom T, Rubin K, Heldin C-H, Ostman A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-443.
31. Kilic T, Alberta JA, Zdunek PR etal. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000; 60: 5143-5150.
32. Hermansson M, Nistér M, Betsholtz C, Heldin CH, Westermark B, Funa K. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci U S A 1988; 85: 7748-7752.
33. Ding H, Wu X, Kim I, Tam PP, Koh GY, Nagy A. The mouse Pdgfc gene: dynamic expression in embryonic tissues during organogenesis. Mech Dev 2000; 96: 209-213.
34. Li X, Tjwa M, Moons L etal. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 2005; 115: 118-127.
35. Zwerner JP, May WA. Dominant negative PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene 2002; 21: 3847-3854.
36. Anderberg C, Li H, Fredriksson L etal. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res 2009; 69: 369-378.
37. Crawford Y, Kasman I, Yu L etal. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
38. Lejbkowicz F, Goldberg-Cohen I, Levy AP. New horizons for VEGF. Is there a role for nuclear localization? Acta Histochem 2005; 106: 405-411.
39. Li W, Keller G. VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J Cell Sci 2000; 113: 1525-1534.
40. Hou X, Kumar A, Lee C etal. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. Proc Natl Acad Sci U S A 2010; 107: 12216-12221.
41. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111: 1287-1295.
42. Di Tomaso E, London N, Fuja D etal. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PloS One 2009; 4: e5123.
43. Di Tomaso E, Snuderl M, Kamoun WS etal. Glioblastoma recurrence after cediranib therapy in patients: lack of «rebound» revascularization as mode of escape. Cancer Res 2011; 71: 19-28.
44. Soda Y, Myskiw C, Rommel A, Verma IM. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med Berl Ger 2013; 91: 439-448.
45. McCarty JH. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res 2013; 19: 1631-1633.